bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Table S5. from Therapeutic Targeting of TFE3/IRS-1/PI3K/mTOR Axis in Translocation Renal Cell Carcinoma
Authors: Damayanti Nur P. , Budka Justin A. , Khella Heba W.Z , Ferris Mary W. , Ku Sheng Yu , Kauffman Eric , Wood Anthony C. , Ahmed Khunsha , Chintala Venkata Nithinsai , Adelaiye-Ogala Remi , Elbanna May , Orillion Ashley , Chintala Sreenivasulu , Kao Chinghai , Linehan W. Marston , Yousef George M. , Hollenhorst Peter C. , Pili Roberto
Published: April 2023

Comprehensive panels of 403 WIKI tools pathways identified by bioinformatics analysis of TFE3 ChIP-seq peaks in RP-R07 cells.
Supplementary Table S2. from Therapeutic Targeting of TFE3/IRS-1/PI3K/mTOR Axis in Translocation Renal Cell Carcinoma
Authors: Damayanti Nur P. , Budka Justin A. , Khella Heba W.Z , Ferris Mary W. , Ku Sheng Yu , Kauffman Eric , Wood Anthony C. , Ahmed Khunsha , Chintala Venkata Nithinsai , Adelaiye-Ogala Remi , Elbanna May , Orillion Ashley , Chintala Sreenivasulu , Kao Chinghai , Linehan W. Marston , Yousef George M. , Hollenhorst Peter C. , Pili Roberto
Published: April 2023

Lists of significant TFE3 peaks and corresponding genes identified by ChIP-seq in RP-R07 cells and RP-R07 tumor.
Supplementary Data from Activated and Exhausted MAIT Cells Foster Disease Progression and Indicate Poor Outcome in Hepatocellular Carcinoma
Authors: Duan Meng , Goswami Shyamal , Shi Jie-Yi , Wu Lin-Jie , Wang Xiao-Ying , Ma Jia-Qiang , Zhang Zhao , Shi Yang , Ma Li-Jie , Zhang Shu , Xi Rui-Bin , Cao Ya , Zhou Jian , Fan Jia , Zhang Xiao-Ming , Gao Qiang
Published: April 2023

Supplementary Table S6
Supplementary Appendix A-F: additional results from Accuracy, Safety, and Reliability of Novel Phase I Trial Designs
Authors: Zhou Heng , Yuan Ying , Nie Lei
Published: April 2023

Additional results
Supplementary Fig. 6 from Therapeutic Targeting of TFE3/IRS-1/PI3K/mTOR Axis in Translocation Renal Cell Carcinoma
Authors: Damayanti Nur P. , Budka Justin A. , Khella Heba W.Z , Ferris Mary W. , Ku Sheng Yu , Kauffman Eric , Wood Anthony C. , Ahmed Khunsha , Chintala Venkata Nithinsai , Adelaiye-Ogala Remi , Elbanna May , Orillion Ashley , Chintala Sreenivasulu , Kao Chinghai , Linehan W. Marston , Yousef George M. , Hollenhorst Peter C. , Pili Roberto
Published: April 2023

Effect of different rapamycin concentrations
Table S3 from Capecitabine Efficacy Is Correlated with TYMP and RB1 Expression in PDX Established from Triple-Negative Breast Cancers
Authors: Marangoni Elisabetta , Laurent Cécile , Coussy Florence , El-Botty Rania , Château-Joubert Sophie , Servely Jean-Luc , de Plater Ludmilla , Assayag Franck , Dahmani Ahmed , Montaudon Elodie , Nemati Fariba , Fleury Justine , Vacher Sophie , Gentien David , Rapinat Audrey , Foidart Pierre , Sounni Nor Eddine , Noel Agnès , Vincent-Salomon Anne , Lae Marick , Decaudin Didier , Roman-Roman Sergio , Bièche Ivan , Piccart Martine , Reyal Fabien
Published: April 2023

List of genes differentially regulated between resistant and responder PDX.
Table S2 from Capecitabine Efficacy Is Correlated with TYMP and RB1 Expression in PDX Established from Triple-Negative Breast Cancers
Authors: Marangoni Elisabetta , Laurent Cécile , Coussy Florence , El-Botty Rania , Château-Joubert Sophie , Servely Jean-Luc , de Plater Ludmilla , Assayag Franck , Dahmani Ahmed , Montaudon Elodie , Nemati Fariba , Fleury Justine , Vacher Sophie , Gentien David , Rapinat Audrey , Foidart Pierre , Sounni Nor Eddine , Noel Agnès , Vincent-Salomon Anne , Lae Marick , Decaudin Didier , Roman-Roman Sergio , Bièche Ivan , Piccart Martine , Reyal Fabien
Published: April 2023

Clinical characteristics of patients
Table S1 from Capecitabine Efficacy Is Correlated with TYMP and RB1 Expression in PDX Established from Triple-Negative Breast Cancers
Authors: Marangoni Elisabetta , Laurent Cécile , Coussy Florence , El-Botty Rania , Château-Joubert Sophie , Servely Jean-Luc , de Plater Ludmilla , Assayag Franck , Dahmani Ahmed , Montaudon Elodie , Nemati Fariba , Fleury Justine , Vacher Sophie , Gentien David , Rapinat Audrey , Foidart Pierre , Sounni Nor Eddine , Noel Agnès , Vincent-Salomon Anne , Lae Marick , Decaudin Didier , Roman-Roman Sergio , Bièche Ivan , Piccart Martine , Reyal Fabien
Published: April 2023

Take rate of residual tumors as compared to primary tumors
Figure S2 from Capecitabine Efficacy Is Correlated with TYMP and RB1 Expression in PDX Established from Triple-Negative Breast Cancers
Authors: Marangoni Elisabetta , Laurent Cécile , Coussy Florence , El-Botty Rania , Château-Joubert Sophie , Servely Jean-Luc , de Plater Ludmilla , Assayag Franck , Dahmani Ahmed , Montaudon Elodie , Nemati Fariba , Fleury Justine , Vacher Sophie , Gentien David , Rapinat Audrey , Foidart Pierre , Sounni Nor Eddine , Noel Agnès , Vincent-Salomon Anne , Lae Marick , Decaudin Didier , Roman-Roman Sergio , Bièche Ivan , Piccart Martine , Reyal Fabien
Published: April 2023

A)Response to cisplatin in the HBcx-66 (BRCA1-mutated) and HBCx-92 (BRCA2-mutated) PDX. B) KM survival analysis of the HBCx-95 PDX
Supplementary Data from Efficacy of Combined VEGFR1-3, PDGFα/β, and FGFR1-3 Blockade Using Nintedanib for Esophagogastric Cancer
Authors: Won Elizabeth , Basunia Azfar , Chatila Walid K. , Hechtman Jaclyn F. , Chou Joanne F. , Ku Geoffrey Y. , Chalasani Sree B. , Boyar Michelle S. , Goldberg Zoe , Desai Avni M. , Tuvy Yaelle , Berger Michael F. , Tang Laura , Kelsen David P. , Schattner Mark , Ilson David H. , Capanu Marinela , Solit David B. , Schultz Nikolaus , Janjigian Yelena Y.
Published: April 2023

Supplementary Table 3
Supplementary Figure S3: Heat Map of Cohort from Genomic Heterogeneity and the Small Renal Mass
Authors: Ueno Daiki , Xie Zuoquan , Boeke Marta , Syed Jamil , Nguyen Kevin A. , McGillivray Patrick , Adeniran Adebowale , Humphrey Peter , Dancik Garrett M. , Kluger Yuval , Liu Zongzhi , Kluger Harriet , Shuch Brian
Published: April 2023

Figure S3 shows heat map of samples-sample distance for entire gene set.
Supplementary Table S1. from Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor–Positive Advanced Breast Cancer
Authors: Dickler Maura N. , Saura Cristina , Richards Donald A. , Krop Ian E. , Cervantes Andrés , Bedard Philippe L. , Patel Manish R. , Pusztai Lajos , Oliveira Mafalda , Cardenas Alison K. , Cui Na , Wilson Timothy R. , Stout Thomas J. , Wei Michael C. , Hsu Jerry Y. , Baselga José
Published: April 2023

Study disposition
Supplementary Figure S1: Analysis of the total of CNV events by region for the five mixed ccA/B tumors. from Genomic Heterogeneity and the Small Renal Mass
Authors: Ueno Daiki , Xie Zuoquan , Boeke Marta , Syed Jamil , Nguyen Kevin A. , McGillivray Patrick , Adeniran Adebowale , Humphrey Peter , Dancik Garrett M. , Kluger Yuval , Liu Zongzhi , Kluger Harriet , Shuch Brian
Published: April 2023

Analysis in 5 mixed ccA/ccB tumors including 15 regions showed that CNVs were more frequent among ccB reagions(p=0.014).
Supplemental Methods from Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor–Positive Advanced Breast Cancer
Authors: Dickler Maura N. , Saura Cristina , Richards Donald A. , Krop Ian E. , Cervantes Andrés , Bedard Philippe L. , Patel Manish R. , Pusztai Lajos , Oliveira Mafalda , Cardenas Alison K. , Cui Na , Wilson Timothy R. , Stout Thomas J. , Wei Michael C. , Hsu Jerry Y. , Baselga José
Published: April 2023

Definition of adverse events of special interest (AESI)
Supplementary Data 4 from Pan-Cancer Molecular Classes Transcending Tumor Lineage Across 32 Cancer Types, Multiple Data Platforms, and over 10,000 Cases
Authors: Chen Fengju , Zhang Yiqun , Gibbons Don L. , Deneen Benjamin , Kwiatkowski David J. , Ittmann Michael , Creighton Chad J.
Published: April 2023

By patient, pathway-associated and immune-associated gene signature scorings. Also included are pathway signature gene sets. Provided as an Excel file.
Supplementary Table 2 from SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity
Authors: Boysen Gunther , Rodrigues Daniel N. , Rescigno Pasquale , Seed George , Dolling David , Riisnaes Ruth , Crespo Mateus , Zafeiriou Zafeiris , Sumanasuriya Semini , Bianchini Diletta , Hunt Joanne , Moloney Deirdre , Perez-Lopez Raquel , Tunariu Nina , Miranda Susana , Figueiredo Inês , Ferreira Ana , Christova Rossitza , Gil Veronica , Aziz Sara , Bertan Claudia , de Oliveira Flavia M. , Atkin Mark , Clarke Matthew , Goodall Jane , Sharp Adam , MacDonald Theresa , Rubin Mark A. , Yuan Wei , Barbieri Christopher E. , Carreira Suzanne , Mateo Joaquin , de Bono Johann S.
Published: April 2023

Baseline values at start of abiraterone
Supplementary Data 2 from Pan-Cancer Molecular Classes Transcending Tumor Lineage Across 32 Cancer Types, Multiple Data Platforms, and over 10,000 Cases
Authors: Chen Fengju , Zhang Yiqun , Gibbons Don L. , Deneen Benjamin , Kwiatkowski David J. , Ittmann Michael , Creighton Chad J.
Published: April 2023

Patient-level platform availability and subtyping features, along with top features by each platform used in the molecular classification analyses. Provided as an Excel file.
Supplementary 6 from Pan-Cancer Molecular Classes Transcending Tumor Lineage Across 32 Cancer Types, Multiple Data Platforms, and over 10,000 Cases
Authors: Chen Fengju , Zhang Yiqun , Gibbons Don L. , Deneen Benjamin , Kwiatkowski David J. , Ittmann Michael , Creighton Chad J.
Published: April 2023

Pan-cancer class assignments and pathway-associated gene signature scorings, for each of the expression profiles in the expO (GSE2109) dataset. Provided as an Excel file.
Supplementary Figure 1 from SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity
Authors: Boysen Gunther , Rodrigues Daniel N. , Rescigno Pasquale , Seed George , Dolling David , Riisnaes Ruth , Crespo Mateus , Zafeiriou Zafeiris , Sumanasuriya Semini , Bianchini Diletta , Hunt Joanne , Moloney Deirdre , Perez-Lopez Raquel , Tunariu Nina , Miranda Susana , Figueiredo Inês , Ferreira Ana , Christova Rossitza , Gil Veronica , Aziz Sara , Bertan Claudia , de Oliveira Flavia M. , Atkin Mark , Clarke Matthew , Goodall Jane , Sharp Adam , MacDonald Theresa , Rubin Mark A. , Yuan Wei , Barbieri Christopher E. , Carreira Suzanne , Mateo Joaquin , de Bono Johann S.
Published: April 2023

Sample overview
Legends supplementary figures/ tables from SPOP-Mutated/CHD1-Deleted Lethal Prostate Cancer and Abiraterone Sensitivity
Authors: Boysen Gunther , Rodrigues Daniel N. , Rescigno Pasquale , Seed George , Dolling David , Riisnaes Ruth , Crespo Mateus , Zafeiriou Zafeiris , Sumanasuriya Semini , Bianchini Diletta , Hunt Joanne , Moloney Deirdre , Perez-Lopez Raquel , Tunariu Nina , Miranda Susana , Figueiredo Inês , Ferreira Ana , Christova Rossitza , Gil Veronica , Aziz Sara , Bertan Claudia , de Oliveira Flavia M. , Atkin Mark , Clarke Matthew , Goodall Jane , Sharp Adam , MacDonald Theresa , Rubin Mark A. , Yuan Wei , Barbieri Christopher E. , Carreira Suzanne , Mateo Joaquin , de Bono Johann S.
Published: April 2023

Supplementary figure and table legends
Supplementary Table S1: phase 2 and 3 studies targeting the IGF axis from Bad to the Bone: The Role of the Insulin-Like Growth Factor Axis in Osseous Metastasis
Authors: Rieunier Guillaume , Wu Xiaoning , Macaulay Valentine M. , Lee Adrian V. , Weyer-Czernilofsky Ulrike , Bogenrieder Thomas
Published: April 2023

Table S1 summarises phase 2 and 3 studies targeting the IGF axis
Supplementary Figure 6 from A Coclinical Radiogenomic Validation Study: Conserved Magnetic Resonance Radiomic Appearance of Periostin-Expressing Glioblastoma in Patients and Xenograft Models
Authors: Zinn Pascal O. , Singh Sanjay K. , Kotrotsou Aikaterini , Hassan Islam , Thomas Ginu , Luedi Markus M. , Elakkad Ahmed , Elshafeey Nabil , Idris Tagwa , Mosley Jennifer , Gumin Joy , Fuller Gregory N. , de Groot John F. , Baladandayuthapani Veera , Sulman Erik P. , Kumar Ashok J. , Sawaya Raymond , Lang Frederick F. , Piwnica-Worms David , Colen Rivka R.
Published: April 2023

Supplementary Figure 6
supplementary figures from Telatinib Is an Effective Targeted Therapy for Pseudomyogenic Hemangioendothelioma
Authors: van IJzendoorn David G.P. , Sleijfer Stefan , Gelderblom Hans , Eskens Ferry A.L.M. , van Leenders Geert J.L.H. , Szuhai Karoly , Bovée Judith V.M.G.
Published: April 2023

Supplementary figure 1 Tube formation assay after 24 hours on matrigel with overexpression of indicated proteins using a lentiviral system. Truncated FOSB is most efficient at driving tube formation. Bottom right panel: Western blot of FOSB and truncated FOSB overexpression in HUVECs as detected with a Flag antibody showing effective transduction of both plasmids. Supplementary figure 2 (a) Expression levels of FOSB in the PHE tumor biopsy were compared to normal control HUVECs by real-time qPCR. Both show high expression of FOSB. Expression was normalized against HPRT1. (b) Expression levels of the indicated target genes and receptors were determined in the PHE tumor biopsy compared to normal control HUVECs by real-time qPCR. FAS, JAG, HEY1, FLT1 and PDGFRA were upregulated while VWF was downregulated. ADAMTS13 was not detected in the PHE tumor biopsy. Expression was normalized against HPRT1. Supplementary figure 3 Top panels show cell cycle analysis by analysis of DAPI signal intensity. Gating was performed to identify sub-G1, G1, S-phase and G2 cell fractions. Bottom panels show apoptotic cell fraction as determined by analysis of the PI and VB-48 signal intensity. Apoptotic cell fraction was determined by gating cells negative for PI and VB-48. Supplementary figure 4 (a) Top panel shows 3D assay on matrigel with normal HUVECs and with HUVECs overexpressing truncated FOSB. ShRNA for KIT efficiently blocks tube formation in the normal HUVECs only, while knockdown of KDR shows no effect in either condition. Bottom part of the panel shows the calculated number of loops and junctions of the tube formation assay. (b) IHC of the patient tumor biopsy with a KIT antibody. Tumor cells are negative for KIT while the arrow indicates a mast cell functioning as an internal control.
Supplementary Figure 4 from A Coclinical Radiogenomic Validation Study: Conserved Magnetic Resonance Radiomic Appearance of Periostin-Expressing Glioblastoma in Patients and Xenograft Models
Authors: Zinn Pascal O. , Singh Sanjay K. , Kotrotsou Aikaterini , Hassan Islam , Thomas Ginu , Luedi Markus M. , Elakkad Ahmed , Elshafeey Nabil , Idris Tagwa , Mosley Jennifer , Gumin Joy , Fuller Gregory N. , de Groot John F. , Baladandayuthapani Veera , Sulman Erik P. , Kumar Ashok J. , Sawaya Raymond , Lang Frederick F. , Piwnica-Worms David , Colen Rivka R.
Published: April 2023

Supplementary Figure 4
E1-E6 and TABLE 1 from Radiomics Signature on Magnetic Resonance Imaging: Association with Disease-Free Survival in Patients with Invasive Breast Cancer
Authors: Park Hyunjin , Lim Yaeji , Ko Eun Sook , Cho Hwan-ho , Lee Jeong Eon , Han Boo-Kyung , Ko Eun Young , Choi Ji Soo , Park Ko Woon
Published: April 2023

Appendix E1 The Acquisition Parameters and Retrieving Procedure Appendix E2 MR Imaging Preparation for Radiomic Analysis Appendix E3 MR Imaging Interpretation Appendix E4 Computer code used to compute the Radiomics Features Appendix E5 Categorical Concepts of Radiomic Features and the Mathematical Definition of Adopted Feature Algorithms Appendix E6 Radiomics Score (Rad-score) Calculation Formula
Supplementary Movie (low delta) from A Visually Apparent and Quantifiable CT Imaging Feature Identifies Biophysical Subtypes of Pancreatic Ductal Adenocarcinoma
Authors: Koay Eugene J. , Lee Yeonju , Cristini Vittorio , Lowengrub John S. , Kang Ya'an , Lucas F. Anthony San , Hobbs Brian P. , Ye Rong , Elganainy Dalia , Almahariq Muayad , Amer Ahmed M. , Chatterjee Deyali , Yan Huaming , Park Peter C. , Rios Perez Mayrim V. , Li Dali , Garg Naveen , Reiss Kim A. , Yu Shun , Chauhan Anil , Zaid Mohamed , Nikzad Newsha , Wolff Robert A. , Javle Milind , Varadhachary Gauri R. , Shroff Rachna T. , Das Prajnan , Lee Jeffrey E. , Ferrari Mauro , Maitra Anirban , Taniguchi Cullen M. , Kim Michael P. , Crane Christopher H. , Katz Matthew H. , Wang Huamin , Bhosale Priya , Tamm Eric P. , Fleming Jason B.
Published: April 2023

Mathematical model simulation of low delta tumor growth (lambda = 0.2)
Table S5 from Inhibition of BET Bromodomain Proteins with GS-5829 and GS-626510 in Uterine Serous Carcinoma, a Biologically Aggressive Variant of Endometrial Cancer
Authors: Bonazzoli Elena , Predolini Federica , Cocco Emiliano , Bellone Stefania , Altwerger Gary , Menderes Gulden , Zammataro Luca , Bianchi Anna , Pettinella Francesca , Riccio Francesco , Han Chanhee , Yadav Ghanshyam , Lopez Salvatore , Manzano Aranzazu , Manara Paola , Buza Natalia , Hui Pei , Wong Serena , Litkouhi Babak , Ratner Elena , Silasi Dan-Arin , Huang Gloria S. , Azodi Masoud , Schwartz Peter E. , Schlessinger Joseph , Santin Alessandro D.
Published: April 2023

Average quantitative nuclear histological score associated with the ex vivo c-Myc expression assessed by IHC in the ARK2 xenograft tumor samples, excised 1 hour, 6 hours and 12 hours after the last dose of GS-5829 at 20, 10 mg/kg, JQ1 at 50 mg/kg and vehicle for oral gavage studies, following 28 days of treatment.
Table S2 from Inhibition of BET Bromodomain Proteins with GS-5829 and GS-626510 in Uterine Serous Carcinoma, a Biologically Aggressive Variant of Endometrial Cancer
Authors: Bonazzoli Elena , Predolini Federica , Cocco Emiliano , Bellone Stefania , Altwerger Gary , Menderes Gulden , Zammataro Luca , Bianchi Anna , Pettinella Francesca , Riccio Francesco , Han Chanhee , Yadav Ghanshyam , Lopez Salvatore , Manzano Aranzazu , Manara Paola , Buza Natalia , Hui Pei , Wong Serena , Litkouhi Babak , Ratner Elena , Silasi Dan-Arin , Huang Gloria S. , Azodi Masoud , Schwartz Peter E. , Schlessinger Joseph , Santin Alessandro D.
Published: April 2023

Groups and dosing description of the in vivo drug study on USC-ARK2 xenograft.
Table S1 from Inhibition of BET Bromodomain Proteins with GS-5829 and GS-626510 in Uterine Serous Carcinoma, a Biologically Aggressive Variant of Endometrial Cancer
Authors: Bonazzoli Elena , Predolini Federica , Cocco Emiliano , Bellone Stefania , Altwerger Gary , Menderes Gulden , Zammataro Luca , Bianchi Anna , Pettinella Francesca , Riccio Francesco , Han Chanhee , Yadav Ghanshyam , Lopez Salvatore , Manzano Aranzazu , Manara Paola , Buza Natalia , Hui Pei , Wong Serena , Litkouhi Babak , Ratner Elena , Silasi Dan-Arin , Huang Gloria S. , Azodi Masoud , Schwartz Peter E. , Schlessinger Joseph , Santin Alessandro D.
Published: April 2023

Cell lines characteristics and tissue source.
Figure S2 from Inhibition of BET Bromodomain Proteins with GS-5829 and GS-626510 in Uterine Serous Carcinoma, a Biologically Aggressive Variant of Endometrial Cancer
Authors: Bonazzoli Elena , Predolini Federica , Cocco Emiliano , Bellone Stefania , Altwerger Gary , Menderes Gulden , Zammataro Luca , Bianchi Anna , Pettinella Francesca , Riccio Francesco , Han Chanhee , Yadav Ghanshyam , Lopez Salvatore , Manzano Aranzazu , Manara Paola , Buza Natalia , Hui Pei , Wong Serena , Litkouhi Babak , Ratner Elena , Silasi Dan-Arin , Huang Gloria S. , Azodi Masoud , Schwartz Peter E. , Schlessinger Joseph , Santin Alessandro D.
Published: April 2023

Ex vivo c-Myc expression assessed by IHC on the ARK2 xenograft tumor samples, excised 1 hour, 6 hours and 12 hours after the last dose of GS-5829 at 20, 10 mg/kg, JQ1 at 50 mg/kg and vehicle for oral gavage studies, following 28 days of treatment.
Figure S1 from Inhibition of BET Bromodomain Proteins with GS-5829 and GS-626510 in Uterine Serous Carcinoma, a Biologically Aggressive Variant of Endometrial Cancer
Authors: Bonazzoli Elena , Predolini Federica , Cocco Emiliano , Bellone Stefania , Altwerger Gary , Menderes Gulden , Zammataro Luca , Bianchi Anna , Pettinella Francesca , Riccio Francesco , Han Chanhee , Yadav Ghanshyam , Lopez Salvatore , Manzano Aranzazu , Manara Paola , Buza Natalia , Hui Pei , Wong Serena , Litkouhi Babak , Ratner Elena , Silasi Dan-Arin , Huang Gloria S. , Azodi Masoud , Schwartz Peter E. , Schlessinger Joseph , Santin Alessandro D.
Published: April 2023

Ex vivo c-Myc expression assessed by IHC on the ARK2 xenograft tumor samples, excised 1 hour and 6 hours after a single dose of GS-5829 at 40, 20, 10 mg/kg, GS-626510 at 10 mg/kg and vehicle for oral gavage studies.
Supplementary Data from Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial
Authors: Rothé Françoise , Silva Maria Joao , Venet David , Campbell Christine , Bradburry Ian , Rouas Ghizlane , de Azambuja Evandro , Maetens Marion , Fumagalli Debora , Rodrik-Outmezguine Vanessa , Di Cosimo Serena , Rosa Daniela , Chia Stephen , Wardley Andrew , Ueno Takayuki , Janni Wolfgang , Huober Jens , Baselga Jose , Piccart Martine , Loi Sherene , Sotiriou Christos , Dawson Sarah-Jane , Ignatiadis Michail
Published: April 2023

Supplementary materials and methods
Figure S1 from Magnetic Resonance Imaging of Tumor-Associated Macrophages: Clinical Translation
Authors: Aghighi Maryam , Theruvath Ashok J. , Pareek Anuj , Pisani Laura L. , Alford Raphael , Muehe Anne M. , Sethi Tarsheen K. , Holdsworth Samantha J. , Hazard Florette K. , Gratzinger Dita , Luna-Fineman Sandra , Advani Ranjana , Spunt Sheri L. , Daldrup-Link Heike E.
Published: April 2023

Figure S1 shows the method of semi-automated TAM quantification after CD68 stain on a light microscopic image. (A) CD 68+ macrophage stain (brown) of a lymphoma shows homogenous distribution. (B) and (C) Segmented areas (red) of CD68+ macrophages after using a color thresholding level in Image J. Scale bars, 50µm.
Supplementary material from A Model of Overall Survival Predicts Treatment Outcomes with Atezolizumab versus Chemotherapy in Non–Small Cell Lung Cancer Based on Early Tumor Kinetics
Authors: Claret Laurent , Jin Jin Y. , Ferté Charles , Winter Helen , Girish Sandhya , Stroh Mark , He Pei , Ballinger Marcus , Sandler Alan , Joshi Amita , Rittmeyer Achim , Gandara David , Soria Jean-Charles , Bruno René
Published: April 2023

Supplementary Figure S1-S6; Supplementary Table S1-S2
Figure S2 from Androgen Deprivation Therapy Potentiates the Efficacy of Vascular Targeted Photodynamic Therapy of Prostate Cancer Xenografts
Authors: Kim Kwanghee , Watson Philip A. , Lebdai Souhil , Jebiwott Sylvia , Somma Alexander J. , La Rosa Stephen , Mehta Dipti , Murray Katie S. , Lilja Hans , Ulmert David , Monette Sebastien , Scherz Avigdor , Coleman Jonathan A.
Published: April 2023

CD31 vessel staining of tumors treated with VTP or VTP/ADT combination
Supplementary table 4 from Clinically Relevant and Minimally Invasive Tumor Surveillance of Pediatric Diffuse Midline Gliomas Using Patient-Derived Liquid Biopsy
Authors: Panditharatna Eshini , Kilburn Lindsay B. , Aboian Mariam S. , Kambhampati Madhuri , Gordish-Dressman Heather , Magge Suresh N. , Gupta Nalin , Myseros John S. , Hwang Eugene I. , Kline Cassie , Crawford John R. , Warren Katherine E. , Cha Soonmee , Liang Winnie S. , Berens Michael E. , Packer Roger J. , Resnick Adam C. , Prados Michael , Mueller Sabine , Nazarian Javad
Published: April 2023

Clinical information for PNOC003 plasma ctDNA studies.
Figure S1 from Androgen Deprivation Therapy Potentiates the Efficacy of Vascular Targeted Photodynamic Therapy of Prostate Cancer Xenografts
Authors: Kim Kwanghee , Watson Philip A. , Lebdai Souhil , Jebiwott Sylvia , Somma Alexander J. , La Rosa Stephen , Mehta Dipti , Murray Katie S. , Lilja Hans , Ulmert David , Monette Sebastien , Scherz Avigdor , Coleman Jonathan A.
Published: April 2023

ADT reduces tumor proliferation measured by Ki67
Supplementary Table 5. from Cell-Free DNA Modification Dynamics in Abiraterone Acetate-Treated Prostate Cancer Patients
Authors: Gordevičius Juozas , Kriščiūnas Algimantas , Groot Daniel E. , Yip Steven M. , Susic Miki , Kwan Andrew , Kustra Rafal , Joshua Anthony M. , Chi Kim N. , Petronis Art , Oh Gabriel
Published: April 2023

List of significant AA-DVPs.
Supplementary Table 3 from Cell-Free DNA Modification Dynamics in Abiraterone Acetate-Treated Prostate Cancer Patients
Authors: Gordevičius Juozas , Kriščiūnas Algimantas , Groot Daniel E. , Yip Steven M. , Susic Miki , Kwan Andrew , Kustra Rafal , Joshua Anthony M. , Chi Kim N. , Petronis Art , Oh Gabriel
Published: April 2023

List of significant AA-DMPs at FDR q < 0.2.
Supplementary Data from Engineering the TGFβ Receptor to Enhance the Therapeutic Potential of Natural Killer Cells as an Immunotherapy for Neuroblastoma
Authors: Burga Rachel A. , Yvon Eric , Chorvinsky Elizabeth , Fernandes Rohan , Cruz C. Russell Y. , Bollard Catherine M.
Published: April 2023

Supplementary Table 1: NK cell persistence. Fig. S1. Characterizing SHSY5Y neuroblastoma. Fig. S2. NK cell functionality against HTLA230 neuroblastoma. Fig. S3. Verification of NK Cell Sorting. Fig. S4. NK Cell Phenotype and Proliferation. Fig. S5. NK cell phenotype following TGFbeta exposure. Fig. S6. Neuroblastoma tumor progression and the correlation between progression-free survival and NK cell persistence. Fig. S7. NK cell detection in neuroblastoma-bearing mice. Supplementary Materials and Methods.
Supplemental Figure S3 from Multimodality Treatment of Desmoplastic Small Round Cell Tumor: Chemotherapy and Complete Cytoreductive Surgery Improve Patient Survival
Authors: Subbiah Vivek , Lamhamedi-Cherradi Salah-Eddine , Cuglievan Branko , Menegaz Brian A. , Camacho Pamela , Huh Winston , Ramamoorthy Vandhana , Anderson Pete M. , Pollock Raphael E. , Lev Dina C. , Qiao Wei , McAleer Mary Frances , Benjamin Robert S. , Patel Shreyaskumar , Herzog Cynthia E. , Daw Najat C. , Feig Barry W. , Lazar Alexander J. , Hayes-Jordan Andrea , Ludwig Joseph A.
Published: April 2023

Subset analysis of the impact of HIPEC (A) and WART (B) in patients achieved CCR0 from CCS
Supplemental Figures from Tryptophan Metabolism Contributes to Radiation-Induced Immune Checkpoint Reactivation in Glioblastoma
Authors: Kesarwani Pravin , Prabhu Antony , Kant Shiva , Kumar Praveen , Graham Stewart F. , Buelow Katie L. , Wilson George D. , Miller C. Ryan , Chinnaiyan Prakash
Published: April 2023

Supplemental Figures 1, 2, 3 and 4
Supplementary Data from RAB37 Hypermethylation Regulates Metastasis and Resistance to Docetaxel-Based Induction Chemotherapy in Nasopharyngeal Carcinoma
Authors: Li Yingqin , Yang Xiaojing , Du Xiaojing , Lei Yuan , He Qingmei , Hong Xiaohong , Tang Xinran , Wen Xin , Zhang Panpan , Sun Ying , Zhang Jian , Wang Yaqin , Ma Jun , Liu Na
Published: April 2023

Supplementary Data from RAB37 Hypermethylation Regulates Metastasis and Resistance to Docetaxel-Based Induction Chemotherapy in Nasopharyngeal Carcinoma
Supplementary Document from Chemotherapy Sensitizes Therapy-Resistant Cells to Mild Hyperthermia by Suppressing Heat Shock Protein 27 Expression in Triple-Negative Breast Cancer
Authors: Mu Chaofeng , Wu Xiaoyan , Zhou Xinyu , Wolfram Joy , Shen Jianliang , Zhang Dechen , Mai Junhua , Xia Xiaojun , Holder Ashley M. , Ferrari Mauro , Liu Xuewu , Shen Haifa
Published: April 2023

Supplementary Data Supplementary Methods Fig. S1. Increased CD44+CD24-ESA+ cell subpopulation in (A) SUM159 and (B) MDA-MB-231 cells after docetaxel treatment. *, p< 0.05; **, p< 0.01 (compared to untreatment controls). Analysis of apoptotic (C) SUM159 and (D) MDA-MB-231 cells 24 hours after cells were treated with DTX for 8 hours followed by hyperthermia at 43ï,°C for 5 min. *, p< 0.05; **, p< 0.01. The mean and standard deviations were calculated from three replicates. Fig. S2. NIR-triggered heat generation by AuPSMs. (A) Different efficiency on heat generation by different size Au particles in PSM. (B) Photothermal effect is stable and can be repeated for multiple cycles with the 20 nm Au particles in PSM. - Fig. S3. Quantitative RT-PCR analysis of heat shock protein expression in three ALDH1-positive breast cancer cell lines. (A) HSP27, HSP70 and HSP90 mRNA levels in ALDH1-positive MDA-MB-231 cells. (B) Dose-dependent killing of murine 4T1 cells treated with increasing concentrations of DTX for 72 hours. (C) HSP25 (murine homologue of human HSP27), HSP70 and HSP90 mRNA levels in ALDH1-positive 4T1 cells. (D) Dose-dependent killing of drug resistant MDA-MB-231/MDR cells treated with increasing concentrations of DTX for 72 hours. (E) HSP27, HSP70 and HSP90 mRNA levels in ALDH1-positive MDA-MB-231/MDR cells. All cells were treated with DTX for 8 hours followed by mild hyperthermia at 43ï,°C for 5 min.
Figure S1-S7, Table S1-S5 from CDK9 Inhibitor FIT-039 Suppresses Viral Oncogenes E6 and E7 and Has a Therapeutic Effect on HPV-Induced Neoplasia
Authors: Ajiro Masahiko , Sakai Hiroyuki , Onogi Hiroshi , Yamamoto Makoto , Sumi Eriko , Sawada Teruo , Nomura Takashi , Kabashima Kenji , Hosoya Takamitsu , Hagiwara Masatoshi
Published: April 2023

Figure S1-S7, Table S1-S5
Supplementary Figure 3 from Combinations of Bevacizumab and Erlotinib Show Activity in Colorectal Cancer Independent of RAS Status
Authors: Mésange Paul , Bouygues Anaïs , Ferrand Nathalie , Sabbah Michèle , Escargueil Alexandre E. , Savina Ariel , Chibaudel Benoist , Tournigand Christophe , André Thierry , de Gramont Aimery , Larsen Annette K.
Published: April 2023

The influence of 72 hrs exposure to vehicle, erlotinib (Erlo, 10 µM) or cetuximab (Cetux, 1 µg/mL) on the viability of the indicated CRC cell lines as measured by the TUNEL assay.
Supplementary Figure 2 from Combinations of Bevacizumab and Erlotinib Show Activity in Colorectal Cancer Independent of RAS Status
Authors: Mésange Paul , Bouygues Anaïs , Ferrand Nathalie , Sabbah Michèle , Escargueil Alexandre E. , Savina Ariel , Chibaudel Benoist , Tournigand Christophe , André Thierry , de Gramont Aimery , Larsen Annette K.
Published: April 2023

The expression of total VEGFR1 and VEGFR2 was determined by ELISA analysis of tumor extracts (3 tumors per treatment).
Supplementary Figure 1 from Combinations of Bevacizumab and Erlotinib Show Activity in Colorectal Cancer Independent of RAS Status
Authors: Mésange Paul , Bouygues Anaïs , Ferrand Nathalie , Sabbah Michèle , Escargueil Alexandre E. , Savina Ariel , Chibaudel Benoist , Tournigand Christophe , André Thierry , de Gramont Aimery , Larsen Annette K.
Published: April 2023

Influence of bevacizumab (Beva), erlotinib (Erlo) and their combination (Beva + Erlo) on the tumor growth of CRC xenografts.
Supplementary Table and Figure Legends from Clinical Utility of Prospective Molecular Characterization in Advanced Endometrial Cancer
Authors: Soumerai Tara E. , Donoghue Mark T.A. , Bandlamudi Chaitanya , Srinivasan Preethi , Chang Matthew T. , Zamarin Dmitriy , Cadoo Karen A. , Grisham Rachel N. , O'Cearbhaill Roisin E. , Tew William P. , Konner Jason A. , Hensley Martee L. , Makker Vicky , Sabbatini Paul , Spriggs David R. , Troso-Sandoval Tiffany A. , Charen Alexandra Snyder , Friedman Claire , Gorsky Mila , Schweber Sarah J. , Middha Sumit , Murali Rajmohan , Chiang Sarah , Park Kay J. , Soslow Robert A. , Ladanyi Marc , Li Bob T. , Mueller Jennifer , Weigelt Britta , Zehir Ahmet , Berger Michael F. , Abu-Rustum Nadeem R. , Aghajanian Carol , DeLair Deborah F. , Solit David B. , Taylor Barry S. , Hyman David M.
Published: April 2023

Supplementary Table and Figure Legends
Table S3 from A Pan-cancer Landscape of Interactions between Solid Tumors and Infiltrating Immune Cell Populations
Authors: Tamborero David , Rubio-Perez Carlota , Muiños Ferran , Sabarinathan Radhakrishnan , Piulats Josep M. , Muntasell Aura , Dienstmann Rodrigo , Lopez-Bigas Nuria , Gonzalez-Perez Abel
Published: April 2023

Pan-cancer and per-cancer type GSVA scores for immune populations
Supplementary Figure S1 from High-Fat Diet-Induced Inflammation Accelerates Prostate Cancer Growth via IL6 Signaling
Authors: Hayashi Takuji , Fujita Kazutoshi , Nojima Satoshi , Hayashi Yujiro , Nakano Kosuke , Ishizuya Yu , Wang Cong , Yamamoto Yoshiyuki , Kinouchi Toshiro , Matsuzaki Kyosuke , Jingushi Kentaro , Kato Taigo , Kawashima Atsunari , Nagahara Akira , Ujike Takeshi , Uemura Motohide , Pena Maria Del Carmen Rodriguez , Gordetsky Jennifer B. , Morii Eiichi , Tsujikawa Kazutake , Netto George J. , Nonomura Norio
Published: April 2023

Prostate weights, H&E staining and local immune cells of normal and Pten-deficient model mice
Supplementary Tables from Phase I Trials of Anti-ENPP3 Antibody–Drug Conjugates in Advanced Refractory Renal Cell Carcinomas
Authors: Thompson John A. , Motzer Robert J. , Molina Ana M. , Choueiri Toni K. , Heath Elisabeth I. , Redman Bruce G. , Sangha Randeep S. , Ernst D. Scott , Pili Roberto , Kim Stella K. , Reyno Leonard , Wiseman Aya , Trave Fabio , Anand Banmeet , Morrison Karen , Doñate Fernando , Kollmannsberger Christian K.
Published: April 2023

Supplementary Tables
Supplementary Figure 5 from Phase I Trials of Anti-ENPP3 Antibody–Drug Conjugates in Advanced Refractory Renal Cell Carcinomas
Authors: Thompson John A. , Motzer Robert J. , Molina Ana M. , Choueiri Toni K. , Heath Elisabeth I. , Redman Bruce G. , Sangha Randeep S. , Ernst D. Scott , Pili Roberto , Kim Stella K. , Reyno Leonard , Wiseman Aya , Trave Fabio , Anand Banmeet , Morrison Karen , Doñate Fernando , Kollmannsberger Christian K.
Published: April 2023

Supplementary Figure 5. Serum concentration time profiles for AGS-16M8F(Hyb) Total Antibody (TAb) (data is presented as Mean {plus minus} SD)
Table S1 from Inositol Trisphosphate Receptor Type 3-mediated Enhancement of EGFR and MET Cotargeting Efficacy in Non–Small Cell Lung Cancer Detected by 18F-fluorothymidine
Authors: Iommelli Francesca , De Rosa Viviana , Terlizzi Cristina , Monti Marcello , Panico Mariarosaria , Fonti Rosa , Del Vecchio Silvana
Published: April 2023

Supplementary Table 1. Levels of IP3R3 and signaling mediators by densitometric analysis of western blots. The optical density of each band was normalized to the same parameter derived from the corresponding tubulin control using ImageJ software and reported as relative protein level compared to the corresponding internal control. Three independent siRNA transfection of H1993 cells were analyzed, data were pooled and expressed as mean {plus minus} SE.
Supplementary Table S3 from Comprehensive Liquid Profiling of Circulating Tumor DNA and Protein Biomarkers in Long-Term Follow-Up Patients with Hepatocellular Carcinoma
Authors: Cai Zhixiong , Chen Geng , Zeng Yongyi , Dong Xiuqing , Li Zhenli , Huang Yanbing , Xin Fuli , Qiu Liman , Xu Haipo , Zhang Wei , Su Xiaoping , Liu Xiaolong , Liu Jingfeng
Published: April 2023

Associations between the postoperative ctDNA/protein biomarker levels and clinicopathological characteristics of 34 enrolled patients.
Figure S3 from NKG2D Controls Natural Reactivity of Vγ9Vδ2 T Lymphocytes against Mesenchymal Glioblastoma Cells
Authors: Chauvin Cynthia , Joalland Noémie , Perroteau Jeanne , Jarry Ulrich , Lafrance Laura , Willem Catherine , Retière Christelle , Oliver Lisa , Gratas Catherine , Gautreau-Rolland Laetitia , Saulquin Xavier , Vallette François M. , Vié Henri , Scotet Emmanuel , Pecqueur Claire
Published: April 2023

Allogeneic human VÎ³9VÎ'2 T lymphocytes reduce primary tumor progression in vivo.
Supplementary Data from An Integrative Approach to Inform Optimal Administration of OX40 Agonist Antibodies in Patients with Advanced Solid Tumors
Authors: Wang Rui , Gao Chan , Raymond Megan , Dito Gennaro , Kabbabe Dominic , Shao Xiao , Hilt Ed , Sun Yongliang , Pak Irene , Gutierrez Martin , Melero Ignacio , Spreafico Anna , Carvajal Richard D. , Ong Michael , Olszanski Anthony J. , Milburn Christina , Thudium Kent , Yang Zheng , Feng Yan , Fracasso Paula M. , Korman Alan J. , Aanur Praveen , Huang Shih-Min A. , Quigley Michael
Published: April 2023

Supplemental Figure 11
SUPPLEMENTARY FIGURE AND TABLE LEGENDS from Early Enrichment of ESR1 Mutations and the Impact on Gene Expression in Presurgical Primary Breast Cancer Treated with Aromatase Inhibitors
Authors: Leal Mariana Ferreira , Haynes Ben P. , Schuster Eugene , Yeo Belinda , Afentakis Maria , Zabaglo Lila , Martins Vera , Buus Richard , Dodson Andrew , Cheang Maggie C.U. , Smith Ian E. , Martin Lesley-Ann , Dowsett Mitch
Published: April 2023

SUPPLEMENTARY FIGURE (1-7) AND TABLE (1-12) LEGENDS
Supplementary data from A Phase I Study of the Anti-CC Chemokine Receptor 4 Antibody, Mogamulizumab, in Combination with Nivolumab in Patients with Advanced or Metastatic Solid Tumors
Authors: Doi Toshihiko , Muro Kei , Ishii Hiroshi , Kato Terufumi , Tsushima Takahiro , Takenoyama Mitsuhiro , Oizumi Satoshi , Gemmoto Kazuto , Suna Hideaki , Enokitani Kouki , Kawakami Tetsuyoshi , Nishikawa Hiroyoshi , Yamamoto Noboru
Published: April 2023

Supplementary methods and results
Table S8 from Interaction between Molecular Subtypes and Stromal Immune Infiltration before and after Treatment in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy
Authors: Hamy Anne-Sophie , Bonsang-Kitzis Hélène , De Croze Diane , Laas Enora , Darrigues Lauren , Topciu Lucian , Menet Emmanuelle , Vincent-Salomon Anne , Lerebours Florence , Pierga Jean-Yves , Brain Etienne , Feron Jean-Guillaume , Benchimol Gabriel , Lam Giang-Thanh , Laé Marick , Reyal Fabien
Published: April 2023

Table S8
Figure S7 from A T-cell–engaging B7-H4/CD3-bispecific Fab-scFv Antibody Targets Human Breast Cancer
Authors: Iizuka Akira , Nonomura Chizu , Ashizawa Tadashi , Kondou Ryota , Ohshima Keiichi , Sugino Takashi , Mitsuya Koichi , Hayashi Nakamasa , Nakasu Yoko , Maruyama Kouji , Yamaguchi Ken , Akiyama Yasuto
Published: April 2023

B7-H4 IHC study of human breast cancer tissues FFPE array
Table S5 from Interaction between Molecular Subtypes and Stromal Immune Infiltration before and after Treatment in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy
Authors: Hamy Anne-Sophie , Bonsang-Kitzis Hélène , De Croze Diane , Laas Enora , Darrigues Lauren , Topciu Lucian , Menet Emmanuelle , Vincent-Salomon Anne , Lerebours Florence , Pierga Jean-Yves , Brain Etienne , Feron Jean-Guillaume , Benchimol Gabriel , Lam Giang-Thanh , Laé Marick , Reyal Fabien
Published: April 2023

Table S5
Table S4 from Interaction between Molecular Subtypes and Stromal Immune Infiltration before and after Treatment in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy
Authors: Hamy Anne-Sophie , Bonsang-Kitzis Hélène , De Croze Diane , Laas Enora , Darrigues Lauren , Topciu Lucian , Menet Emmanuelle , Vincent-Salomon Anne , Lerebours Florence , Pierga Jean-Yves , Brain Etienne , Feron Jean-Guillaume , Benchimol Gabriel , Lam Giang-Thanh , Laé Marick , Reyal Fabien
Published: April 2023

Table S4
Table S3 from Interaction between Molecular Subtypes and Stromal Immune Infiltration before and after Treatment in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy
Authors: Hamy Anne-Sophie , Bonsang-Kitzis Hélène , De Croze Diane , Laas Enora , Darrigues Lauren , Topciu Lucian , Menet Emmanuelle , Vincent-Salomon Anne , Lerebours Florence , Pierga Jean-Yves , Brain Etienne , Feron Jean-Guillaume , Benchimol Gabriel , Lam Giang-Thanh , Laé Marick , Reyal Fabien
Published: April 2023

Table S3
Figure S3 from A T-cell–engaging B7-H4/CD3-bispecific Fab-scFv Antibody Targets Human Breast Cancer
Authors: Iizuka Akira , Nonomura Chizu , Ashizawa Tadashi , Kondou Ryota , Ohshima Keiichi , Sugino Takashi , Mitsuya Koichi , Hayashi Nakamasa , Nakasu Yoko , Maruyama Kouji , Yamaguchi Ken , Akiyama Yasuto
Published: April 2023

Fab-scFv BsAb-mediated breast cancer cell lysis by MACS isolated or deplete human T cell subsets
Supplementary Table 3 from Noninvasive Detection of Microsatellite Instability and High Tumor Mutation Burden in Cancer Patients Treated with PD-1 Blockade
Authors: Georgiadis Andrew , Durham Jennifer N. , Keefer Laurel A. , Bartlett Bjarne R. , Zielonka Magdalena , Murphy Derek , White James R. , Lu Steve , Verner Ellen L. , Ruan Finey , Riley David , Anders Robert A. , Gedvilaite Erika , Angiuoli Sam , Jones Siân , Velculescu Victor E. , Le Dung T. , Diaz Luis A. , Sausen Mark
Published: April 2023

Comparison of Microsatellite Status Determined through FFPE Tissue Analyses
Supplementary Figure 3 from Noninvasive Detection of Microsatellite Instability and High Tumor Mutation Burden in Cancer Patients Treated with PD-1 Blockade
Authors: Georgiadis Andrew , Durham Jennifer N. , Keefer Laurel A. , Bartlett Bjarne R. , Zielonka Magdalena , Murphy Derek , White James R. , Lu Steve , Verner Ellen L. , Ruan Finey , Riley David , Anders Robert A. , Gedvilaite Erika , Angiuoli Sam , Jones Siân , Velculescu Victor E. , Le Dung T. , Diaz Luis A. , Sausen Mark
Published: April 2023

Plasma-Based Progression Free Survival Analysis for Patients Treated with Immune Checkpoint Blockade.
Supplementary Figure 1 from Noninvasive Detection of Microsatellite Instability and High Tumor Mutation Burden in Cancer Patients Treated with PD-1 Blockade
Authors: Georgiadis Andrew , Durham Jennifer N. , Keefer Laurel A. , Bartlett Bjarne R. , Zielonka Magdalena , Murphy Derek , White James R. , Lu Steve , Verner Ellen L. , Ruan Finey , Riley David , Anders Robert A. , Gedvilaite Erika , Angiuoli Sam , Jones Siân , Velculescu Victor E. , Le Dung T. , Diaz Luis A. , Sausen Mark
Published: April 2023

Archival Tissue-Based Detection of Microsatellite Instability and High Tumor Mutation Burden.
Supplementary Data from Sorafenib Population Pharmacokinetics and Skin Toxicities in Children and Adolescents with Refractory/Relapsed Leukemia or Solid Tumor Malignancies
Authors: Inaba Hiroto , Panetta John C. , Pounds Stanley B. , Wang Lei , Li Lie , Navid Fariba , Federico Sara M. , Eisenmann Eric D. , Vasilyeva Aksana , Wang Yong-Dong , Shurtleff Sheila , Pui Ching-Hon , Gruber Tanja A. , Ribeiro Raul C. , Rubnitz Jeffrey E. , Baker Sharyn D.
Published: April 2023

Supplementary Figures and Tables
Supplementary Data from Evaluation of Residual Disease and TKI Duration Are Critical Predictive Factors for Molecular Recurrence after Stopping Imatinib First-line in Chronic Phase CML Patients
Authors: Nicolini Franck Emmanuel , Dulucq Stéphanie , Boureau Lisa , Cony-Makhoul Pascale , Charbonnier Aude , Escoffre-Barbe Martine , Rigal-Huguet Françoise , Coiteux Valérie , Varet Bruno , Dubruille Viviane , Lenain Pascal , Rousselot Philippe , Rea Delphine , Guerci-Bresler Agnès , Legros Laurence , Liu Jixing , Gardembas Martine , Ianotto Jean-Christophe , Turlure Pascal , Johnson-Ansah Hyacinthe , Martiniuc Juliana , Jardel Henry , Joly Bertrand , Zunic Patricia , Henni Tawfiq , Villemagne Bruno , Berger Marc G. , Cayssials Emilie , Guilhot François , Larosa Fabrice , Guilhot Joëlle , Etienne Gabriel , Mahon François-Xavier
Published: April 2023

Supplemental table 1: Sequence of hydrolysis probes and primers used for the ddPCR.
Supplementary Table 4 from Acquired Resistance Mutations to ALK Inhibitors Identified by Single Circulating Tumor Cell Sequencing in ALK-Rearranged Non–Small-Cell Lung Cancer
Authors: Pailler Emma , Faugeroux Vincent , Oulhen Marianne , Mezquita Laura , Laporte Mélanie , Honoré Aurélie , Lecluse Yann , Queffelec Pauline , NgoCamus Maud , Nicotra Claudio , Remon Jordi , Lacroix Ludovic , Planchard David , Friboulet Luc , Besse Benjamin , Farace Françoise
Published: April 2023

Supplementary Table 4
Supplementary Table 3 from Acquired Resistance Mutations to ALK Inhibitors Identified by Single Circulating Tumor Cell Sequencing in ALK-Rearranged Non–Small-Cell Lung Cancer
Authors: Pailler Emma , Faugeroux Vincent , Oulhen Marianne , Mezquita Laura , Laporte Mélanie , Honoré Aurélie , Lecluse Yann , Queffelec Pauline , NgoCamus Maud , Nicotra Claudio , Remon Jordi , Lacroix Ludovic , Planchard David , Friboulet Luc , Besse Benjamin , Farace Françoise
Published: April 2023

Supplementary Table 3
Supplementary Figure Legends from Adaptive Resistance to Dual BRAF/MEK Inhibition in BRAF-Driven Tumors through Autocrine FGFR Pathway Activation
Authors: Wang Victoria E. , Xue Jenny Y. , Frederick Dennie T. , Cao Yi , Lin Eva , Wilson Catherine , Urisman Anatoly , Carbone David P. , Flaherty Keith T. , Bernards Rene , Lito Piro , Settleman Jeff , McCormick Frank
Published: April 2023

Supplementary Figure Legends
Supplementary Figure 5 from Acquired Resistance Mutations to ALK Inhibitors Identified by Single Circulating Tumor Cell Sequencing in ALK-Rearranged Non–Small-Cell Lung Cancer
Authors: Pailler Emma , Faugeroux Vincent , Oulhen Marianne , Mezquita Laura , Laporte Mélanie , Honoré Aurélie , Lecluse Yann , Queffelec Pauline , NgoCamus Maud , Nicotra Claudio , Remon Jordi , Lacroix Ludovic , Planchard David , Friboulet Luc , Besse Benjamin , Farace Françoise
Published: April 2023

Supplementary Figure 5
Supplementary Figure 1 from Acquired Resistance Mutations to ALK Inhibitors Identified by Single Circulating Tumor Cell Sequencing in ALK-Rearranged Non–Small-Cell Lung Cancer
Authors: Pailler Emma , Faugeroux Vincent , Oulhen Marianne , Mezquita Laura , Laporte Mélanie , Honoré Aurélie , Lecluse Yann , Queffelec Pauline , NgoCamus Maud , Nicotra Claudio , Remon Jordi , Lacroix Ludovic , Planchard David , Friboulet Luc , Besse Benjamin , Farace Françoise
Published: April 2023

Supplementary Figure 1
Supplementary Figure S1-S3. from Alterations in DNA Damage Repair Genes in Primary Liver Cancer
Authors: Lin Jianzhen , Shi Junping , Guo Honglin , Yang Xu , Jiang Yan , Long Junyu , Bai Yi , Wang Dongxu , Yang Xiaobo , Wan Xueshuai , Zhang Lei , Pan Jie , Hu Ke , Guan Mei , Huo Li , Sang Xinting , Wang Kai , Zhao Haitao
Published: April 2023

Supplementary Figure S1-S3.
Figure S1 from Clinical Genomic Sequencing of Pediatric and Adult Osteosarcoma Reveals Distinct Molecular Subsets with Potentially Targetable Alterations
Authors: Suehara Yoshiyuki , Alex Deepu , Bowman Anita , Middha Sumit , Zehir Ahmet , Chakravarty Debyani , Wang Lu , Jour George , Nafa Khedoudja , Hayashi Takuo , Jungbluth Achim A. , Frosina Denise , Slotkin Emily , Shukla Neerav , Meyers Paul , Healey John H. , Hameed Meera , Ladanyi Marc
Published: April 2023

KDR immunohistochemical stain in OS with 4q12 amplification
Supplementary Figure 2 from Molecular Profiling of Hepatocellular Carcinoma Using Circulating Cell-Free DNA
Authors: Kaseb Ahmed O. , Sánchez Nora S. , Sen Shiraj , Kelley Robin K. , Tan Benjamin , Bocobo Andrea G. , Lim Kian H. , Abdel-Wahab Reham , Uemura Marc , Pestana Roberto Carmagnani , Qiao Wei , Xiao Lianchun , Morris Jeffrey , Amin Hesham M. , Hassan Manal M. , Rashid Asif , Banks Kimberly C. , Lanman Richard B. , Talasaz AmirAli , Mills-Shaw Kenna R. , George Bhawana , Haque Abedul , Raghav Kanwal P.S. , Wolff Robert A. , Yao James C. , Meric-Bernstam Funda , Ikeda Sadakatsu , Kurzrock Razelle
Published: April 2023

Supplementary Figure 2
Table S1 from TFEB Mediates Immune Evasion and Resistance to mTOR Inhibition of Renal Cell Carcinoma via Induction of PD-L1
Authors: Zhang Cai , Duan Yaqi , Xia Minghui , Dong Yuting , Chen Yufei , Zheng Lu , Chai Shuaishuai , Zhang Qian , Wei Zhengping , Liu Na , Wang Jing , Sun Chaoyang , Tang Zhaohui , Cheng Xiang , Wu Jie , Wang Guoping , Zheng Fang , Laurence Arian , Li Bing , Yang Xiang-Ping
Published: April 2023

Patient characteristics
Figure S5 from TFEB Mediates Immune Evasion and Resistance to mTOR Inhibition of Renal Cell Carcinoma via Induction of PD-L1
Authors: Zhang Cai , Duan Yaqi , Xia Minghui , Dong Yuting , Chen Yufei , Zheng Lu , Chai Shuaishuai , Zhang Qian , Wei Zhengping , Liu Na , Wang Jing , Sun Chaoyang , Tang Zhaohui , Cheng Xiang , Wu Jie , Wang Guoping , Zheng Fang , Laurence Arian , Li Bing , Yang Xiang-Ping
Published: April 2023

Effects of combinational inhibition of PD-L1 and mTOR on tumor cell proliferation and IFN-γ production in CD8+ T cells
Figure S1 from TFEB Mediates Immune Evasion and Resistance to mTOR Inhibition of Renal Cell Carcinoma via Induction of PD-L1
Authors: Zhang Cai , Duan Yaqi , Xia Minghui , Dong Yuting , Chen Yufei , Zheng Lu , Chai Shuaishuai , Zhang Qian , Wei Zhengping , Liu Na , Wang Jing , Sun Chaoyang , Tang Zhaohui , Cheng Xiang , Wu Jie , Wang Guoping , Zheng Fang , Laurence Arian , Li Bing , Yang Xiang-Ping
Published: April 2023

No effect of TFEB on RCC tumor cell growth, proliferation and migration